CGC-11047

DRUG2 trials

Sponsors

Progen Pharmaceuticals, University of Wisconsin, Madison

Conditions

Age Related Macular DegenerationProstate Cancer

Phase 1

Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD

CompletedNCT00446654

Progen PharmaceuticalsAge Related Macular Degeneration

Start: 2007-04-30End: 2007-10-31Updated: 2012-08-06

Phase 2

Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer

TerminatedNCT00585416

University of Wisconsin, MadisonProstate Cancer

Start: 2006-06-30End: 2009-03-31Updated: 2015-10-02